Pollinex Quattro Tree: allergy vaccine

An overview of short-term specific immunotherapy (ST-SIT) highlighting Pollinex Quattro (PQ) Tree is presented. The product development of this novel allergy vaccine using modifying agent glutaraldehyde, adjuvant monophosphoryl lipid and L-tyrosine have heralded a superior ST-SIT. Since 1999 when PQ was founded in Germany, various research trials assessing both the standardization and clinical studies have been done. A review of these studies demonstrates the efficacy and safety of PQ Tree in both pediatric and adult trials. The uniqueness of this product allows a shorter course of four pre-seasonal injections to provide control of allergy symptomatology in seasonal rhinitis patients. The PQ Tree product studies show a similar efficacy and safety profile to the grass formulation trial.